Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 6/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407021 | 1.00 | DHFR (0.45) | DHFRMLYCDDGAT1SLC18A3KDM6B | |
| SCHEMBL29377211 | 0.81 | MAPT (0.44) | RET | |
| SCHEMBL21916945 | 0.81 | MAPT (0.44) | RET | |
| SCHEMBL23972249 | 0.80 | GRIN2D (0.52) | DHFRMLYCD | |
| SCHEMBL17442208 | 0.80 | MAPT (0.54) | TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL22117672 | 0.78 | GRIN2B (0.51) | DHFRMLYCDDGAT1SLC18A3CYP2D6 | |
| SCHEMBL2393500 | 0.78 | DHFR (0.55) | DHFRMLYCDDGAT1SLC18A3SLC6A3 | |
| SCHEMBL3307866 | 0.78 | HRH3 (0.51) | DHFRMLYCDDGAT1TSHRSMN1; SMN2 | |
| SCHEMBL23972404 | 0.77 | RET (0.47) | DGAT1RETTSHRSMN1; SMN2SIGMAR1 | |
| SCHEMBL29377204 | 0.77 | UBE2T (0.51) | SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2023-10-26 | — | — | US | disclosed |
| CN-115427409-A | Pyrimidin-4 (3H) -one derivatives as TRPV4 antagonists | 拉夸里亚创药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021221169-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | RAQUALIA PHARMA INC. (JP) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339934-A1 | PYRIMIDIN-4(3H)-ONE DERIVATIVES AS TRPV4 ANTAGONISTS | TRPV4, TRPV1, TRPV2 | DHFR 950/4885MLYCD 4315/4885DGAT1 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.